Back to Journals » OncoTargets and Therapy » Volume 12

The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy [Corrigendum]

Authors Yang M, Qin X, Qin G, Zheng X 

Received 17 April 2019

Accepted for publication 17 April 2019

Published 5 July 2019 Volume 2019:12 Pages 5375—5376

DOI https://doi.org/10.2147/OTT.S212592



Yang M, Qin X, Qin G, Zheng X. Onco Targets Ther. 2019;12:2171–2180.

 

On page 2172, Chemotherapy regimens section in Table 1, Platinum + platinum (TP) should have been Docetaxel + platinum (TP); Platinum + cyclophosphamide (TC) should have been Docetaxel + cyclophosphamide (TC). 

 

Read the original article

 

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.